HopeStage
Back to all studies
CompletedNCT05066672

NV-5138 study for treatment-resistant depression in adults

About this titleRead the official source — NCT05066672

This study evaluated the safety and effectiveness of NV-5138 for people with depression.

Medication studyAges 18–70United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of NV-5138 for people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Listed locations
BellevueSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 18, 2022
Recruitment status
Completed
Enrollment listed in the registry
250
Sponsor
Navitor Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 70 Years
Official registry ID
NCT05066672
Official title
Show the full official title

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of NV-5138 for people with depression.

Who is behind this study?

The study sponsor is Navitor Pharmaceuticals, Inc.

Did this study involve medication?

Yes. The study involved medication, including NV-5138 and matched placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies